Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

SU 12662

Known as: SU-12662, SU12662 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Interpatient variability in the pharmacokinetics (PK) of sunitinib is high. Single nucleotide polymorphisms (SNPs) in PK… Expand
2014
2014
SummaryIntroduction Sunitinib is a multikinase inhibitor active in various cancers types including renal cancers and endocrine… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Highly Cited
2012
Highly Cited
2012
CONTEXT Treatment of refractory adrenocortical carcinoma (ACC) is not established. Animal experiments pointed toward adrenal… Expand
Review
2012
Review
2012
Sunitinib malate (Sutent®, Pfizer Inc.) is a multitargeted tyrosine kinase inhibitor that inhibits tumor cell proliferation and… Expand
  • figure 9.1
  • figure 9.2
  • table 9.1
  • table 9.2
  • figure 9.3
Highly Cited
2010
Highly Cited
2010
This phase I, open‐label, single‐dose study evaluates the effects of severe renal impairment and end‐stage renal disease (ESRD… Expand
Highly Cited
2010
Highly Cited
2010
A rapid and sensitive ultra performance liquid chromatography/tandem mass spectrometry (UPLC-MS/MS) method has been developed and… Expand
  • figure 1
  • table 1
  • table 2
  • figure 4
Highly Cited
2009
Highly Cited
2009
Purpose: Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor approved for advanced renal cell carcinoma and… Expand
  • table 1
  • table 1
  • table 2
  • table 3
  • table 4
Review
2007
Review
2007
BACKGROUND Sunitinib was approved by the US Food and Drug Administration (FDA) on January 26, 2006, for the treatment of… Expand
Highly Cited
2007
Highly Cited
2007
PurposeSunitinib, an oral multitargeted tyrosine kinase inhibitor that inhibits VEGFR, PDGFR, FLT3, KIT, and RET, is currently… Expand
  • table 1
  • table 3
  • table 2
  • table 4
  • figure 1
Highly Cited
2006
Highly Cited
2006
The effect of food on the oral bioavailability of sunitinib malate (SU11248, an oral, multi-targeted tyrosine kinase inhibitor… Expand